Progyny(PGNY) GlobeNewswire·2025-01-13 13:00Core Viewpoint - Progyny, Inc. anticipates that its fourth quarter and full year results for 2024 will be slightly above previously provided financial guidance, driven by improved member activity and treatment volume [1][3]. Financial Guidance - In November, the company had projected that member activity for the fourth quarter would be flat to down compared to the third quarter [2]. - As the fourth quarter progressed, the company observed favorable pacing in member activity, leading to an expectation of revenue, net income, and Adjusted EBITDA results exceeding prior guidance [3]. Conference Participation - Progyny will present at the 43rd Annual JP Morgan Healthcare Conference on January 14, 2025, where the CEO will discuss updated expectations for the company's performance [4]. Company Overview - Progyny is recognized as a transformative solution in fertility, family building, and women's health benefits, serving leading employers and health plans [6]. - The company emphasizes comprehensive and inclusive solutions that benefit employers, patients, and physicians [6][7]. Recognition and Awards - Progyny has received multiple accolades, including being named a TIME100 Most Influential Company and a CNBC Disruptor 50, highlighting its leadership and growth in the industry [8].